Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructu...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | FILIPCSEI, GENOVEVA HELTOVICS, GABOR OTVOS, ZSOLT DARVAS, FERENC |
| description | The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AU2011266808BB2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AU2011266808BB2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AU2011266808BB23</originalsourceid><addsrcrecordid>eNqNjLEKwkAQRNNYiPoPW1gqJBFC2kQUKyutw3LZmINk99jbVP68CdjYWQ2PeTPr5H1Hlmg6OZuUWqiCUvCGbOBkDBK9eeF4gKDiKEboRMF6gsVDxaVdWEk6QG4h9KgjOprMOxx-TmZgQ8-eX8tk3CarDodIu29ukv318jjfjhSkoRjmFyZrqmeeZlleFGVa1nV--lP7AHkzSpo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them</title><source>esp@cenet</source><creator>FILIPCSEI, GENOVEVA ; HELTOVICS, GABOR ; OTVOS, ZSOLT ; DARVAS, FERENC</creator><creatorcontrib>FILIPCSEI, GENOVEVA ; HELTOVICS, GABOR ; OTVOS, ZSOLT ; DARVAS, FERENC</creatorcontrib><description>The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160204&DB=EPODOC&CC=AU&NR=2011266808B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160204&DB=EPODOC&CC=AU&NR=2011266808B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FILIPCSEI, GENOVEVA</creatorcontrib><creatorcontrib>HELTOVICS, GABOR</creatorcontrib><creatorcontrib>OTVOS, ZSOLT</creatorcontrib><creatorcontrib>DARVAS, FERENC</creatorcontrib><title>Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them</title><description>The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLEKwkAQRNNYiPoPW1gqJBFC2kQUKyutw3LZmINk99jbVP68CdjYWQ2PeTPr5H1Hlmg6OZuUWqiCUvCGbOBkDBK9eeF4gKDiKEboRMF6gsVDxaVdWEk6QG4h9KgjOprMOxx-TmZgQ8-eX8tk3CarDodIu29ukv318jjfjhSkoRjmFyZrqmeeZlleFGVa1nV--lP7AHkzSpo</recordid><startdate>20160204</startdate><enddate>20160204</enddate><creator>FILIPCSEI, GENOVEVA</creator><creator>HELTOVICS, GABOR</creator><creator>OTVOS, ZSOLT</creator><creator>DARVAS, FERENC</creator><scope>EVB</scope></search><sort><creationdate>20160204</creationdate><title>Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them</title><author>FILIPCSEI, GENOVEVA ; HELTOVICS, GABOR ; OTVOS, ZSOLT ; DARVAS, FERENC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AU2011266808BB23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>FILIPCSEI, GENOVEVA</creatorcontrib><creatorcontrib>HELTOVICS, GABOR</creatorcontrib><creatorcontrib>OTVOS, ZSOLT</creatorcontrib><creatorcontrib>DARVAS, FERENC</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FILIPCSEI, GENOVEVA</au><au>HELTOVICS, GABOR</au><au>OTVOS, ZSOLT</au><au>DARVAS, FERENC</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them</title><date>2016-02-04</date><risdate>2016</risdate><abstract>The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_AU2011266808BB2 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A23%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FILIPCSEI,%20GENOVEVA&rft.date=2016-02-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAU2011266808BB2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |